## **Amendments to the Specification:**

Please insert the following paragraph and heading before the first paragraph on page 1:

--This application is a filing under 35 U.S.C. 371 of international application number PCT/NO03/00125, filed April 15, 2003, which claims priority to Norwegian application number 20021886 filed April 19, 2002 and 20023357 filed July 11, 2002, the entire disclosures of which are hereby incorporated by reference.

## Field of Invention--

Please insert the following heading before the paragraph at page 1, line 3.

## -- Background of the Invention--

Please insert the following headings and text before the paragraph at page 3, line 30.

## --Summary of the Invention

In view of the needs of the prior art, the present invention provides a method for determining *in vivo* protein activity comprising the steps of a) hyperpolarising the NMR active nuclei of samples collected from a human or non-human animate body preadministered with at least one probe compound containing at least one NMR active nuclei; and b) analysing the samples by NMR spectroscopy.

The present invention also provides an agent for determining *in vivo* protein activity comprising a mixture comprising at least two probe compounds, all probe compounds being enriched with <sup>13</sup>C and/or <sup>15</sup>N NMR active nuclei.

Preliminary Amdt. Dated October 19, 2004

The present invention still further provides for the manufacture of an agent for determining in vivo protein activity. The agent comprises a mixture including at least two probe compounds, each probe compound being enriched with <sup>13</sup>C and/or <sup>15</sup>N NMR active nuclei.

The present invention even still further provides a mixture comprising at least two probe compounds, all probe compounds being enriched with <sup>13</sup>C and/or <sup>15</sup>N NMR active nuclei, for use as an agent for determining *in vivo* protein activity.

A mixture of the present invention which includes at least two probe compounds may further comprise at least one putative drug.

The mixture of the present invention may be used for the determination of in vivo protein activity, for example, phenotyping. The mixture of the present invention may also be used for studying drug-drug interaction.

Detailed Description of the Preferred Embodiments of the Invention-